MedPath

BioXmark liquid fiducial to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial

Completed
Conditions
rectal tumor
10017990
Registration Number
NL-OMON47645
Lead Sponsor
MAASTRO clinic
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

* patients with histological or cytological proven rectal cancer, treated with long course external beam radiotherapy
* Age 18 year or older
* have given written informed consent

Exclusion Criteria

* iodine allergy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Positional stability of BioXmark liquid fiducial markers during the treatment<br /><br>course</p><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath